The start-ups gained Europe-wide exposure through our Catapult programme. They have now received accelerator grants and equity investments from the European Innovation Council (EIC).
This brings the total number of EIT Health Catapult alumni to receive EIC grants in 2022 to seven. The EIC Accelerator offers start-ups and SMEs grants of up to EUR 2.5M combined with EIC Fund equity investments ranging from EUR 500 000 to EUR 15M. In addition to financial support, the start-ups will gain access to leading experts, corporations, investors, and ecosystem actors who can help their businesses grow. Learn more about the four Catapult alumni who received grants in the last round:
- INNITIUS, semi-finalist in the Catapult MedTech category in 2021
- Avatar Medical, semi-finalist in the Catapult Digital Health category in 2021
- Time is Brain (Digital Health) and Gate2Brain (Biotech), Catapult semi-finalists in 2022
Innitius is a MedTech start-up based in Bilbao, Spain. It aims to help differentiate between false and real preterm labour threats using their portable diagnostic device, FineBirth. They have been granted EUR 3.8M and will use the funding to complete clinical research, begin manufacturing their products, and move through European regulatory pathway processes.
Avatar Medical, based in Paris, France, creates patient avatars to help surgeons prepare for surgery. Their technology instantly makes interactive 3D representations of patients based on standard medical images in an immersive virtual reality. They will use their new funding to accelerate the development of their 3D solution for shorter, safer, and less invasive surgeries.
Time is Brain is a digital health start-up based in Barcelona, Spain, that aims to help stroke patients with their BraiN20(R) solution. The start-up received EUR 2.5M from the EIC Accelerator programme and will use the funding to validate the BraiN20, start industrialising, obtain the CE Mark, and commercialise their product.
Gate2Brain is a biotech start-up based in Barcelona, Spain, that uses its peptide-based patented solution to improve the transport of drugs to the brain. They have been granted EUR 2.5M and will use the funding to navigate the pre-clinical regulations for their flagship product, G2B-002.
Source: European Institute of Innovation & Innovation & Technology (https://bit.ly/3WAuKb4)